Trial reportAntimicrobial agents and chemotherapy2001
Lack of emergence of cytomegalovirus UL97 mutations conferring ganciclovir (GCV) resistance following preemptive GCV therapy in allogeneic stem cell transplant recipients.
Trial report in Antimicrobial agents and chemotherapy, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 41 citations in OpenAlex.
- Article
- Infectious complications after hematopoietic stem cell transplantation: current status and future perspectives in Korea.The Korean journal of internal medicine · 2018Review
- How I treat resistant cytomegalovirus infection in hematopoietic cell transplantation recipients.Blood · 2016Article
- Paradoxical rising cytomegalovirus antigenemia during preemptive ganciclovir therapy in hematopoietic stem cell transplant recipients: incidence, risk factors, and clinical outcomes.Journal of clinical microbiology · 2011Article
- The genetic basis of human cytomegalovirus resistance and current trends in antiviral resistance analysis.Infectious disorders drug targets · 2011Review
- The search for new therapies for human cytomegalovirus infections.Virus research · 2011Review
- Antiviral drug resistance of human cytomegalovirus.Clinical microbiology reviews · 2010Review
- Human cytomegalovirus resistance to antiviral drugs.Antimicrobial agents and chemotherapy · 2005Review
- Prevention of cytomegalovirus disease in recipients of allogeneic stem cell transplants.Clinical microbiology reviews · 2003Review
- High impact of an expanded restriction fragment length polymorphism assay on detection of ganciclovir-resistant UL97 mutants of human cytomegalovirus.Antimicrobial agents and chemotherapy · 2003Article
- Rapid development of ganciclovir-resistant cytomegalovirus infection in children after allogeneic stem cell transplantation in the early phase of immune cell recovery.Bone marrow transplantation · 2002Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fifty allogeneic stem cell transplant recipients were enrolled in a prospective cytomegalovirus pp65 antigenemia-guided preemptive therapy trial. Among these, 10 of 34 patients who received ganciclovir exhibited sustained and/or recurrent antigenemia despite treatment. Thirteen leukocyte preparations from these 10 subjects were screened for the presence of the most frequent cytomegalovirus UL97 mutations conferring ganciclovir resistance. None of these mutations were detected after mean and median ganciclovir exposures of 31.6 and 28.0 days, respectively.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.